| Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2016: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2015: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
We investigated whether geranylgeranylacetone(GGA) protected neonatal lungs from hyperoxic stress in a murine bronchopulmonary dysplasia (BPD) model, and measured serum heat shock protein (HSP)70 levels in preterm humans treated with oxygen. GGA administration enhanced HSP70 expression two-fold compared with normoxia-exposed and vehicle-treated mice. Hyperoxia reduced HSP70 expression, whereas GGA abrogated the effects. Hyperoxia-exposed mice exhibited more apoptotic cells in lung parenchyma and a more simplified alveolar structure with less radial alveolar count (RAC) and larger mean linear intercept (MLI) than normoxia-exposed mice. GGA suppressed the increase in apoptotic cells and the structural changes of the lungs induced by hyperoxia. Serum HSP70 levels of preterm human infants gradually decreased with age.GGA may attenuate hyperoxic injury in neonatal lungs and thereby may prevent the development of BPD.
|
